Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aligos Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALGS
Nasdaq
8731
https://www.aligos.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aligos Therapeutics Inc
Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)
- May 9th, 2024 10:39 am
Aligos Therapeutics Reports Recent Business Progress andĀ First Quarter 2024 Financial Results
- May 7th, 2024 8:05 pm
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
- Apr 30th, 2024 8:05 pm
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
- Apr 25th, 2024 8:05 pm
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
- Apr 25th, 2024 12:00 pm
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
- Apr 9th, 2024 12:00 pm
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Apr 3rd, 2024 12:00 pm
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
- Mar 27th, 2024 1:55 pm
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Mar 27th, 2024 12:00 pm
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Mar 18th, 2024 12:00 pm
Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Mar 14th, 2024 10:16 am
Aligos Therapeutics Reports Recent Business Progress andĀ Fourth Quarter and Full Year 2023 Financial Results
- Mar 12th, 2024 8:05 pm
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
- Mar 5th, 2024 9:05 pm
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
- Feb 26th, 2024 1:00 pm
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
- Feb 20th, 2024 1:00 pm
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
- Feb 13th, 2024 1:00 pm
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
- Jan 5th, 2024 2:40 pm
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
- Dec 7th, 2023 9:05 pm
13 Stocks Insiders are Buying Now
- Nov 24th, 2023 3:26 pm
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
- Nov 20th, 2023 9:05 pm
Scroll